Bristol-Myers Squibb

Bristol-Myers wins $752 million in U.S. patent case against Gilead
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Bristol-Myers Squibb
Gilead Sciences
Kite Pharma
patents
Juno Therapeutics
Flag link:
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Motley Fool
Celgene
M&A
Bristol-Myers Squibb
Flag link:
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Pharmaceutical Business Review
Vedanta Biosciences
VE800
Bristol-Myers Squibb
Opdivo
cancer
clinical trials
Flag link:
Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486
Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486
BioSpace
Bristol-Myers Squibb
CC-486
AML
Flag link:
Deal of the Year: Bristol-Myers Squibb buys Celgene
Deal of the Year: Bristol-Myers Squibb buys Celgene
Biopharma Dive
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
Motley Fool
Bristol-Myers Squibb
Flag link:
Myeloma cell therapies, now in pharma hands, move into spotlight
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
Flag link:
Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Pharmaceutical Business Review
Bristol-Myers Squibb
Orencia
graft vs host disease
FDA
breakthrough status
Flag link:
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
Flag link:
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
Flag link:
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Flag link:
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Stat
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Merck
M&A
Flag link:
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Pharmaceutical Business Review
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Bristol-Myers misses main goal of late-stage skin cancer trial
Bristol-Myers misses main goal of late-stage skin cancer trial
Yahoo/Reuters
Bristol-Myers Squibb
clinical trials
Yervoy
Opdivo
advanced melanoma
Flag link:
Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost
Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost
Fierce Pharma
Pfizer
Eliquis
Bristol-Myers Squibb
atrial fibrillation
Flag link:
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Investors Business Daily
Bristol-Myers Squibb
Celgene
FTC
M&A
Flag link:
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer
Endpoints
Bristol-Myers Squibb
Opdivo
liver cancer
Yervoy
FDA
Flag link:
Nektar shows durability of Opdivo combo in 18-month update
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
Flag link:
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout
Biopharma Dive
ASH
Celgene
M&A
Bristol-Myers Squibb
liso-cel
Flag link:
Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?
Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?
Motley Fool
Merck
Bristol-Myers Squibb
Yervoy
Opdivo
Keytruda
lung cancer
Flag link:

Pages